Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy

Authors

  • Amy Sun

  • Raymond L. Lam

  • Amy Harman

  • Anna C. Pavlick

  • Gary A. Herman

Keywords:

Cell cycle proteins, phosphorylated CDC2, biological markers, biomarkers, proteins, Cells, chemotherapy, cancers

Abstract

This study was to clinically validate phosphorylated CDC2(pCDC2) as a biomarker for Wee1 kinase inhibitors by measuring pCDC2 in skin biopsies from patients receiving DNA damaging chemotherapy. Skin biopsies were performed at scheduled times after chemotherapy. Total CDC2 and pCDC2 in epidermal cells, hair follicle and bulb from skin biopsies were determined using chromogenic multiplex immunohis-tochemistry with multispectral image analysis. Statistical analyses were performed for each cell type after log-transformation of data. Thirty-one patients (29-88 years) completed the study. Significant induction of pCDC2 in response to chemotherapy was detected. Epidermis was most consistently evaluable across skin biopsies, demonstrating strong induction of pCDC2. The percentage of cells positive for total CDC2 and pCDC2 showed a 1.40-fold induction from baseline to 24h post-infusion (p=0.012) and a 2.05-fold increase from baseline to 48h (p

How to Cite

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy. (2014). Global Journal of Medical Research, 14(2), 11-21. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Author Biographies

Amy Sun

Dr. Amy Sun is a physician-scientist specializing in hematology and oncology, currently a Fellow at UCLA Health. She earned her MD-PhD in Medicine and Immunology from NYU Langone Health and a BS in Biology from Stanford University. Her research focuses on cancer biomarkers, including the induction of CDC2 phosphorylation in skin biopsies from patients undergoing DNA-damaging chemotherapy and the level of phosphohistone H3 across various human cancers. With over 40 publications and more than 1,300 citations, Dr. Sun has made significant contributions to the understanding of cancer biology and therapeutic response. She has held positions at Merck & Co., Inc., Stanford Medicine, and NYU Langone Health, and continues to advance the field through her clinical and translational research.

Raymond L. Lam

Raymond L. Lam, Ph.D., is a Principal Scientist in Late Development Statistics at Merck Research Laboratories, where he applies his expertise in biostatistics to advance clinical research. With a career focused on statistical analysis in drug development, Dr. Lam has contributed to numerous studies, including work on CDC2 phosphorylation in skin biopsies from patients undergoing DNA-damaging chemotherapy. His research portfolio spans 23 publications, accumulating over 484 citations, reflecting his impact in the field. He holds an h-index of 11 and an i10-index of 11, underscoring his consistent contributions to biomedical statistics and oncology research.

Amy Harman

Amy Harman is a dedicated researcher affiliated with Merck & Co., Inc., where she contributes to the advancement of biostatistics and oncology research. Her work has focused on the induction of CDC2 phosphorylation in skin biopsies from patients with solid tumors undergoing DNA-damaging chemotherapy, a study that underscores her expertise in translational medicine. With 11 publications and over 350 citations, her research has made a meaningful impact in the field. She maintains an h-index of 7 and an i10-index of 7, reflecting the quality and reach of her contributions. Based in the United States, Amy continues to drive innovation in pharmaceutical research.

Anna C. Pavlick

Dr. Anna C. Pavlick is a distinguished researcher affiliated with Merck & Co., Inc. With over 429 publications and more than 23,600 citations, she has made significant contributions to oncology, particularly in melanoma research and immunotherapy. Her work includes studies on CDC2 phosphorylation in skin biopsies and adjuvant NY-ESO-1 vaccine immunotherapy. She holds an h-index of 69 and an i10-index of 171, reflecting her profound impact on the field.

Gary A. Herman

Gary A. Herman is a prolific researcher affiliated with Merck & Co., Inc., where he has contributed extensively to oncology and pharmacology. With 120 publications and over 8,000 citations, his work has had a significant impact on the scientific community. His h-index of 39 and i10-index of 65 underscore his sustained influence. Notable research includes the induction of CDC2 phosphorylation in skin biopsies from patients undergoing DNA-damaging chemotherapy, as well as network pharmacology studies on traditional medicine formulations. His ongoing work continues to advance understanding of drug mechanisms and therapeutic strategies.

References

O. Hashimoto (2006) Cell cycle regulation by the Wee1 Inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. 6(1), 292. https://doi.org/10.1186/1471-2407-6-292

H. Hirai (2009) Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. 8(11), 2992-3000. https://doi.org/10.1158/1535-7163.mct-09-0463

H. Hirai (2010) MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. 9(7), 514-522. https://doi.org/10.4161/cbt.9.7.11115

Takumi Kawabe (2004) G2 checkpoint abrogators as anticancer drugs. 3(4), 513-519. https://doi.org/10.1158/1535-7163.513.3.4

S. Leijen, J. Beijnen, J. Schellens (2010) Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53- Deficient Tumor Cells to DNADamaging Agents. 5(3), 186-191. https://doi.org/10.2174/157488410791498824

Jun Li, Yuli Wang, Yi Sun, Theodore Lawrence (2002) Wild-Type TP53 Inhibits G2-Phase Checkpoint Abrogation and Radiosensitization Induced by PD0166285, a WEE1 Kinase Inhibitor. 157(3), 322-330. https://doi.org/10.1667/0033-7587(2002)157

S. Mizuarai (2009) Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. 8(1), 34. https://doi.org/10.1186/1476-4598-8-34

Matthew O'connell, Nancy Walworth, Antony Carr (2000) The G2-phase DNA-damage checkpoint. 10(7), 296-303. https://doi.org/10.1016/s0962-8924(00)01773-6

M. Oken (1982) Toxicity and Response: Criteria of the Eastern Cooperative Oncology Group. 5, 649-655.

S. Paul (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. 9(3), 203-214. https://doi.org/10.1038/nrd3078

W. Plunkett, P. Huang, Y. Xu, V. Heinemann, R. Grunewald, V. Gandhi (1995) Gemcitabine: metabolism, mechanisms of action, and selfpotentiation. 22, 3-10.

Geoffrey Shapiro, J. Harper (1999) Anticancer drug targets: cell cycle and checkpoint control. 104(12), 1645-1653. https://doi.org/10.1172/jci9054

D. Tan (2009) Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. 15(5), 406-420. https://doi.org/10.1097/ppo.0b013e3181bd0445

Y. Wang (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. 61, 8211-8217.

J. Yun (1999) p53 Negatively Regulates cdc2 Transcription via the CCAAT-binding NF-Y Transcription Factor. 274(42), 9677-2968. https://doi.org/10.1074/jbc.274.42.29677

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy

Published

2014-01-20

How to Cite

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy. (2014). Global Journal of Medical Research, 14(2), 11-21. https://medicalresearchjournal.org/index.php/GJMR/article/view/